The Zhitong Finance App learned that on December 22, the China Securities Regulatory Commission issued a statement on securities issued overseas by domestic companies and listing filings (initial public offering and full circulation). This week (December 18-22), Baokang Shiyun's proposed listing on the Hong Kong Stock Exchange received materials from the China Securities Regulatory Commission.

The application type for Diakang Shiyun is direct overseas listing. The filing date is December 20, 2023. Haiwen Law Firm is its domestic lawyer. According to the disclosure of the Hong Kong Stock Exchange on November 30, Baokang Shiyun submitted a listing application to the main board of the Hong Kong Stock Exchange. UBS UBS Group, CCB International, and Huatai International are co-sponsors.

According to the prospectus, Baokang Shiyun is an innovation-driven clinical-stage ophthalmology biotechnology company committed to developing novel and differentiated therapies. At the same time, the company is committed to internal discovery, development and commercialization of first-of-its-kind and best-in-class ophthalmology treatments to meet unmet global medical needs.

In terms of research and development, Diokang Shiyun has established a broad and innovative pipeline of seven drug candidates, covering major diseases of the front and back of the eye. Among them, there are four clinical drug candidates (i.e. CBT-001, CBT-009, CBT-006, and CBT-004) and three drug candidates in the preclinical stage (i.e. CBT-007, CBT-145, and CBT-011).